Logo image of BGLC

BIONEXUS GENE LAB CORP (BGLC) Stock Fundamental Analysis

NASDAQ:BGLC - Nasdaq - US0906282076 - Common Stock - Currency: USD

2.73  +0.06 (+2.25%)

After market: 2.62 -0.11 (-4.03%)

Fundamental Rating

3

Overall BGLC gets a fundamental rating of 3 out of 10. We evaluated BGLC against 48 industry peers in the Trading Companies & Distributors industry. While BGLC has a great health rating, there are worries on its profitability. BGLC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BGLC has reported negative net income.
BGLC had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BGLC reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BGLC reported negative operating cash flow in multiple years.
BGLC Yearly Net Income VS EBIT VS OCF VS FCFBGLC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 1M -1M -2M

1.2 Ratios

BGLC has a worse Return On Assets (-8.57%) than 93.75% of its industry peers.
Looking at the Return On Equity, with a value of -10.04%, BGLC is doing worse than 87.50% of the companies in the same industry.
Industry RankSector Rank
ROA -8.57%
ROE -10.04%
ROIC N/A
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
BGLC Yearly ROA, ROE, ROICBGLC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

BGLC has a worse Gross Margin (13.46%) than 93.75% of its industry peers.
In the last couple of years the Gross Margin of BGLC has remained more or less at the same level.
BGLC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
BGLC Yearly Profit, Operating, Gross MarginsBGLC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150 -200

More info and screens

7

2. Health

2.1 Basic Checks

BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGLC has more shares outstanding
The number of shares outstanding for BGLC has been increased compared to 5 years ago.
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGLC Yearly Shares OutstandingBGLC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
BGLC Yearly Total Debt VS Total AssetsBGLC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 2.61 indicates that BGLC is not a great score, but indicates only limited risk for bankruptcy at the moment.
BGLC has a Altman-Z score (2.61) which is comparable to the rest of the industry.
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.61
ROIC/WACCN/A
WACC9.89%
BGLC Yearly LT Debt VS Equity VS FCFBGLC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 2M 4M 6M 8M

2.3 Liquidity

BGLC has a Current Ratio of 4.98. This indicates that BGLC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BGLC (4.98) is better than 93.75% of its industry peers.
A Quick Ratio of 3.99 indicates that BGLC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.99, BGLC belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 3.99
BGLC Yearly Current Assets VS Current LiabilitesBGLC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.86% over the past year.
BGLC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.48%.
BGLC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 115.55% yearly.
EPS 1Y (TTM)77.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BGLC Yearly Revenue VS EstimatesBGLC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGLC Price Earnings VS Forward Price EarningsBGLC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGLC Per share dataBGLC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BGLC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONEXUS GENE LAB CORP

NASDAQ:BGLC (4/17/2025, 8:03:53 PM)

After market: 2.62 -0.11 (-4.03%)

2.73

+0.06 (+2.25%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.99%
Inst Owner Change0%
Ins Owners32.59%
Ins Owner Change0%
Market Cap4.91M
AnalystsN/A
Price TargetN/A
Short Float %4.19%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS5.14
BVpS5.22
TBVpS5.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.57%
ROE -10.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.46%
FCFM N/A
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
F-Score2
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 236.43%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 3.99
Altman-Z 2.61
F-Score2
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)78.3%
Cap/Depr(5y)145.32%
Cap/Sales(3y)0.66%
Cap/Sales(5y)2.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y67.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-619.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-541.16%
OCF growth 3YN/A
OCF growth 5YN/A